Vitiligo

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 14, Issue 4, 2005, Pages 137-145

  Huggins, Richard H ^a   Schwartz, Robert A ^a   Janniger, Camila Krysicka ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; Depigmenting disorders; Vitiligo

Indexed keywords

BLEACHING AGENT; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CORTICOSTEROID; KHELLIN; MELAGENINE; MEQUINOL; MONOBENZONE; PIMECROLIMUS; PLACENTA EXTRACT; PSORALEN; TACROLIMUS; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CELL DESTRUCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRY SKIN; ENDEMIC DISEASE; ERYTHEMA; GENETICS; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; HYPOPIGMENTATION; LEPROSY; LOW LEVEL LASER THERAPY; MELANOCYTE; MONOTHERAPY; NARROW BAND ULTRAVIOLET B RADIATION; ONSET AGE; PHOTOALLERGY; PHOTOTHERAPY; PHOTOTOXICITY; PRURITUS; PUVA; Q SWITCHED ALEXANDRITE LASER; REVIEW; SKIN ATROPHY; SKIN CANCER; SKIN GRAFT; SKIN SCALING; TELANGIECTASIA; ULTRAVIOLET B RADIATION; VITILIGO;

HUMANS; VITILIGO;

EID: 29744467204     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Schwartz RA. Pigmentary disorders. In Conn's Current Therapy, 57th ed, eds: Rakel RE, Bope ET, WB Saunders, Philadelphia, 2005: 995-9.
2. Ortonne JP, Bahdoran P, Fitzpatrick TB, Mosher DB, Hori Y. Hypomelanoses and hypermelanoses. In Fitzpatrick's Dermatology in General Medicine, 6th ed, eds: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, McGraw-Hill Professional, New York, 2003: 839-47.
3. el-Mofty AM, el-Mofty M. Vitiligo: a symptom complex. Int J Dermatol 1980; 19: 237-44.
4. Handa H, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from North India. Ped Dermatol 2003; 20: 107-10.
5. Ramaiah A, Mojamdar MV, Amarnath VM. Vitiligo in the SSK community of Bangalore. Indian J Dermatol Veneroel Lepr 1988; 54: 251-4.
6. Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996; 35: 671-4.
7. Goudie BM, Wilkieson C, Goudie RB. A family study of vitiligo patterns. Scott Med J 1983; 28: 338-42.
8. Hafez M, Sharaf L, Abd-el-Nabi SM. The genetics of vitiligo. Acta Derm Venereol 1983; 63: 249-51.
9. Majumder PP, Das SK, Li CC. A genetical model for vitiligo. Am J Hum Genet 1988; 43: 119-25.
10. Arcos-Burgos M, Parodi E, Salgar M, Bedoya E, Builes J, Jaramillo D, Ceballos G, Uribe A, Rivera N, Rivera D, Fonseca I, Camargo M, Palacio G. Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. Hum Genet 2002; 110: 334-42.
11. Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, Cassiman JJ. Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 2001; 145: 90-4.
12. Ando I, Chi HI, Nakagawa H, Otsuka F. Difference in clinical features and HIA antigens between familial and non-familial vitiligo of non-segmental type. Br J Dermatol 1993; 129: 408-10.
13. Finco OM, Cuccia M, Martinetti G, Ruberto G, Orecchia G, Rabbiosi G. Age of onset in vitiligo: relationship with HLA supratypes. Clin Genet 1991; 39: 48-54.
14. Deng GY, Muir A, Maclaren NK, She JX. Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Gen 1995; 56: 528-34.
15. Prahalad S, Kingsbury DJ, Griffin TA, Cooper BL, Glass DN, Maksymowych WP, Colbert RA. Polymorphism in the MHC- encoded LMP7 gene: association with JRA without functional significance for immunoproteasome assembly. J Rheumatol 2001; 28: 2320-5.
16. Casp CB, She JX, McCormack WT. Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun 2003; 4: 492-9.
17. Blomhoff A, Helen Kemp E, Gawkrodger DJ, Weetman AP, Husebye ES, Akselsen HE, Lie BA, Undlien DE. CTLA4 polymorphisms. Pigment Cell Res 2005; 18: 55-8.
18. Tursen U, Kaya TI, Erdal ME, Derici E, Gunduz O, Ikizoglu G. Association between catechol-O-methyltransferase polymorphism and vitiligo. Arch Dermatol Res 2002; 294: 143-6.
19. Fain PR, Gowan K, LaBerge GS, Alkhateeb A, Stetler GL, Talbert J, Bennett DC, Spritz RA. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Gen 2003; 72: 1560-4.
20. Le Poole IC, Sarangarajan R, Zhao Y, Stennett LS, Brown TL, Sheth P, Mild T, Boissy RE. VIT1, a novel gene associated with vitiligo. Pigment Cell Res 2001; 14: 475-84.
21. Gottumukkala RV, Waterman EA, Herd LM, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH. Autoantibodies in vitiligo patients recognize multiple domains of the melanin-concentrating hormone receptor. J Invest Dermatol 2003; 121: 765-70.
22. Broniarczyk-Dyla G, Arkuszewska C, Omulecki A: Coexistence of vitiligo, morphea and lichen planus in the same patient. Przegl Dermatol 1994; 81: 569-72.
23. Iacovelli P, Sinagra JL, Vidolin AP, Marenda S, Capitanio B, Leone G, Picardo M. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005; 210: 26-30.
24. Kemp EH, Waterman EA, Weetman AP: Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65-77.
25. Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoier-Madson M: High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 1994; 74: 120-3.
26. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-666.
27. Schwartz RA, Janniger CK: Vitligo. Cutis 1997; 60: 239-44.
28. MacKie RM. Vitiligo. In Clinical Dermatology, 5th ed, Oxford University Press, New York, 2003: 227-9.
29. Svitra PP, Perry H. Vogt-Koyanagi-Harada (uveomeningitic) syndrome. In Principles and Practice of Ophthalmology: Clinical Practice v1, eds: Albert DA, Jakobiec FA, WB Saunders, Philadelphia, 1994: chapter 31.
30. Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998; 37: 911-7.
31. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998; 134: 1532-40.
32. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
33. Kemp EH, Waterman EA, Hawes BE, et al: The melanocortin receptor 1, a novel target of autoantibody responses in vitiligo 2002. J Clin Invest 2002; 109: 923-30.
34. Gilhar A, Zelickson B, Ulman Y et al: In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105: 683-6.
35. van den Wijngaard RMJGJ, Wankowicz-Kalinska A, Le Poole IC, Tigges B, Westerhof W, Das PK. Local immune response in skin of generalized vitiligo patients: Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80: 1299-309.
36. Sharquie KE, Mehenna SH, Naji AA, Al-Azzawi H. Inflammatory changes in vitiligo: stage I and II depigmentation. Am J Dermatopathol 2004; 26: 108-12.
37. Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83: 683-95.
38. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ.: Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 1997; 7: 83-95.
39. Koca R, Armutcu F, Altinyazar HC, Gurel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol 2004; 29: 406-9.
40. Gauthier Y, Carlo Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-32.
41. Kitamura R, Tsukamoto K, Harada K, Shimizu A, Shimada S, Kobayashi T, Imokawa G. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/HT protein interactions and the downstream effector, MITF-M. J Pathol 2004; 202: 463-75.
42. Grimes PE. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J Am Acad Dermatol 2004; 51: S5-7.
43. Al'Abadie MS, Warren MA, Bleehen SS, et al. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int J Dermatol 1995; 34: 837-40.
44. Liu PY, Bondesson L, Löntz W et al. The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. Arch Dermatol Res 1996; 288: 670-5.
45. Ramirez-Hernandez M, Marras C, Martinez-Escribano JA. Infliximab-Induced Vitiligo. Dermatology 2005; 210: 79-80.
46. Stevenson CJ. Environmentally induced vitiligo (leucoderma) from depigmenting agents and chemicals. J Toxicol Cutan Ocul Toxic 1984; 3: 299-307.
47. Mathias CGT, Maibach HI, Conant MA: Perioral leukoderma simulating vitiligo from use of a toothpaste containing cinnamic aldehyde. Arch Dermatol 1980; 116: 1172-3.
48. Picardi A, Pasquini P, Cattaruzza MS, Gaetano P, Melchi CF, Baliva G, Camaioni D, Tiago A, Abeni D, Biondi M. Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study. Psychother Psychosom 2003; 72: 150-8.
49. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004; 50: 63-7.
50. Njoo MD, Westerhoff W, Bos JD, Bossuyt PMM. The development of guidelines for the treatment of vitiligo. Arch Dermatol 1999; 135: 1514-21.
51. Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol 2004; 29: 180-4.
52. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UVB phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 2004; 140: 677-83.
53. Hadi SM, Spencer JM, Lebwohl M. The use of the 308-nm excimer laser for the treatment of vitiligo. Dermatol Surg 2004; 30: 983-6.
54. Mulekar SV. Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation. Arch Dermatol 2004; 140: 1211-5.
55. Olsson MJ. What are the needs for transplantation treatment in vitiligo, and how good is it? Arch Dermatol 2004; 140: 1273-4.
56. Singal A, Thami GP, Bhalla M. Watchmaker's pin-vise for manual tattooing of vitiligo. Dermatol Surg 2004; 30: 203-4.
57. Xu AE, Wei XD. Topical melagenine for repigmentation in twenty-two child patients with vitiligo on the scalp. Chinese Med J 2004; 117: 199-201.
58. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
59. Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy JC, Lacour JP, Ortonne JP. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-9.
60. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-3.
61. Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol 1999; 6: 317-20.
62. Cherif F, Azaiz MI, Ben Hamida A, Ben O, Dhari A. Calcipotriol and PUVA as treatment for vitiligo. Dermatol Online J 2003; 9: 4.
63. Camacho F, Mazuecos J. Oral and topical L-phenylalanine, clobetasol propionate and UVA/sunlight: a new study for the treatment of vitiligo. J Drugs Dermatol 2002; 1: 127-31.
64. Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 2004; 30: 1043-5.